Analyst Forecasts For Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Are Surging Higher

Simply Wall StNov 20 19:46

Sangamo Stock Climbs 12% Post-market on FDA Update for ST-503

Seeking AlphaNov 20 05:51

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment

WSJNov 20 05:41

Express News | Sangamo Therapeutics Inc - to Initiate Phase 1/2 Study for St-503 in Mid-2025

BreakingsNov 20 05:15

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

BusinesswireNov 20 05:15

Express News | Sangamo Therapeutics Announces U.S. FDA Clearance of Ind Application for St-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

BreakingsNov 20 05:15